Boussard & Gavaudan Holding Ltd (GBP): NAV(s)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
69
Boussard & Gavaudan Holding Ltd (GBP): NAV(s)

                                      BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares

The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

Close of business 07 Feb 2017.

Estimated NAV

  Euro Shares Sterling Shares
Estimated NAV €  22.4048 £  19.6659
Estimated MTD return  0.63 %  0.63 %
Estimated YTD return  1.17 %  1.16 %
Estimated ITD return  124.05 %  96.66 %

NAV and returns are calculated net of management and performance fees

Market information

Euro Shares Amsterdam (AEX) London (LSE)
Market Close €  17.93 N/A
Premium/discount to estimated NAV  -19.97 % N/A
     
Sterling Shares Amsterdam (AEX) London (LSE)
Market Close N/A GBX 1,580.00
Premium/discount to estimated NAV N/A  -19.66 %

Transactions in own securities purchased into treasury

Ordinary Shares Euro Shares Sterling Shares
Number of shares N/A N/A
Average Price N/A N/A
Range of Price N/A N/A

                                                       

Liquidity Enhancement Agreement Euro Shares Sterling Shares
Number of shares N/A N/A
Average Price N/A N/A

BGHL Capital

BGHL Ordinary Shares Euro Shares Sterling Shares
Shares Outstanding  28,862,115  528,912
Held in treasury  322,842 N/A
Shares Issued  29,184,957  528,912

Estimated BG Fund NAV

Class B Euro Shares (estimated) €  173.7795

The Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.

For further information please contact:

Boussard & Gavaudan Investment Management, LLP. Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.com

The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.

This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.

Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.

You should always bear in mind that:

all investment is subject to risk;

results in the past are no guarantee of future results;

the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and

if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice.

 

This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.

 

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...728682d7ac

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Taseko Mines Earnings: Missed Estimates or Surprising Upside?

Updated Category News Views 144

Taseko Mines (AMEX:TGB) is set to drop its quarterly earnings report on February 18, 2026, and traders are already buzzing about it. The whispers in the hallways suggest a glimmer of hope, with analysts eyeing an earnings per share (EPS) of $0.08—a target that could shift market sentiments depending on how it lands. The last quarter's performance still stings; Taseko...

Continue Reading
Magnet Biomedicine Enhances Research with Simplicis's Ledger™

Updated Category News Views 173

Magnet Biomedicine Partners with Simplicis's Ledger™ Platform Magnet Biomedicine, a pioneering biotechnology firm focused on advancing molecular glue discovery, has recently chosen Simplicis's Ledger™ platform following a thorough assessment of leading alternatives. This decision reflects a commitment to enhancing research operations and optimizing compound management...

Continue Reading
Forecasting Asset Appreciation: Bitcoin and Gold's Potential Rise

Updated Category News Views 114

Understanding Market Dynamics Under Uncertain Political Landscapes In the world of finance, significant political changes can lead to substantial shifts in market dynamics. Recent insights from JPMorgan analysts suggest that a victory for Donald Trump could lead to a spike in both Bitcoin and gold prices. This projection is rooted in growing interest from retail investors...

Continue Reading
Apple and Google Forge a Powerful AI Partnership for Future

Updated Category News Views 73

Apple and Google's Exciting AI Collaboration With the excitement surrounding artificial intelligence expected to surge into 2026, tech enthusiasts and market analysts alike are keenly observing the landscape. The anticipation is mounting as companies evaluate their AI capabilities, looking to distinguish true leaders from those merely riding the wave of hype. In a...

Continue Reading
Podcasting Industry Set to Hit $114 Billion With New Trends

Updated Category News Views 241

Explosive Growth in the Podcasting Market Podcasting continues to gain massive traction, with predictions estimating the market will skyrocket from USD 31.49 billion now to an impressive USD 114.48 billion by 2030. This remarkable growth, with a compound annual growth rate (CAGR) of 29.45%, is driven by several innovative trends reshaping the media landscape....

Continue Reading